ArticleJDS communications2026
High immune responder cows have lower treatment risk and reduced milk loss during highly pathogenic avian influenza H5N1 outbreaks.
Article in JDS communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic analysis of High Immune Response technology and relationships with disease resilience in pigs.Journal of animal science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spillover of highly pathogenic avian influenza (HPAI) hemagglutinin type 5 and neuraminidase type 1 (H5N1) into dairy cattle marks the emergence of a new threat to herd health and production efficiency for North American dairy cattle. To address this challenge, this study evaluated whether genetic selection for improved immune response, using Immunity+ GEBVs, can increase resilience to HPAI H5N1 in commercial dairy herds. Treatment records (n = 15,386) and daily milk yield data (n = 650) were obtained from herd management software from 6 large commercial dairy herds in the United States with confirmed HPAI H5N1 outbreaks. The association between Immunity+ GEBV classes and the likelihood of requiring supportive treatment was assessed using binomial logistic regression, while linear models were used to assess the effects of Immunity+ GEBV class on the length of the milk fluctuation period following treatment and total milk loss during this period. Cows with high Immunity+ GEBVs were 24% less likely to require supportive treatment compared with those with low Immunity+ GEBVs (odds ratio = 0.76; 95% CI: 0.64 to 0.9). High immunity cows also experienced significantly lower milk loss (484.46 kg; 95% CI: 440.61 to 528.30 kg) during the post-treatment fluctuation period compared with low immunity cows (618.10 kg; 95% CI: 561.08 to 675.12 kg). Overall, these findings support the value of selecting for enhanced immune response to improve animal health, reduce production losses, and strengthen economic resilience during disease challenges.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.